Bypass mechanisms of resistance to tyrosine kinase inhibition in chronic myelogenous leukaemia

Current Drug Discovery Technologies

Volumn 11, Issue 2, 2014, Pages 145-153

  Marfe, Gabriella ^a   Di Stefano, Carla ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Apoptosis; CML; Imatinib; MTOR pathway; PBTDs

Indexed keywords

ANTHRAMYCIN; ANTILEUKEMIC AGENT; ANTITHROMBOCYTIC AGENT; BAFETINIB; BCR ABL PROTEIN; BENZOTHIAZEPINE DERIVATIVE; BOSUTINIB; BRADYKININ RECEPTOR AGONIST; CALCIUM CHANNEL BLOCKING AGENT; CALMODULIN INHIBITOR; DASATINIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRROLO[1,2 B][1,2,5] BENZOTHIADIAZEPINE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZEPINE DERIVATIVE;

ANTI LEUKEMIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHEMICAL STRUCTURE; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME INHIBITION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; LEUKEMIA CELL; NONHUMAN; ONCOGENE; ONCOGENE BCR ABL; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZEPINES;

EID: 84900865192     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/1570163811666140212111508     Document Type: Article

References (90)

1. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-3.
2. Melo JV, Deininger MW. Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation. Hematol Oncol Clin North Am 2004; 18: 545-68.
3. Advani AS, Pendergast AM. Bcr-Abl variants: Biological and clinical aspects. Leuk Res 2002; 26: 713-20.
4. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990; 344: 251-3.
5. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-30.
6. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92: 3780-792.
7. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt, and BCRABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189-218.
8. Van Etten RA. Mechanisms of transformation by the BCR-ABL oncogene: New perspectives in the post-imatinib era. Leuk Res 2004; 28 (Suppl) 1: S21-28.
9. Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 2007; 13:1089-97.
10. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935-42.
11. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010; 116: 3758-65.
12. Mello JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 2007; 249: 121-32.
13. Deininger M, Buchdunger E, Druker BJ. The development ofimatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-53.
14. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276-83.
15. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23: 4100-9.
16. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006; 20: 1767-73.
17. Soverini S, Colarossi S, Gnani A, et al. GIMEMA Working Party on Chronic Myeloid Leukemia. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006; 12: 7374-9.
18. La Rosée P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002; 62: 7149-53.
19. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7: 345-56.
20. Hochhaus A, Erben P, Ernst T, Mueller MC. Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol 2007; 44: S15-24.
21. Gorre ME, Sawyers CL. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 2002; 9: 303-7.
22. Hochhaus A. Cytogenetic and molecular mechanisms of resistance to imatinib. Semin Hematol 2003; 40: 69-79.
23. Ramirez P, Dipersio IF. Therapy options in imatinib failures. The Oncologist 2008; 13: 424-34.
24. Barnes DJ, Schultheis B, Adedeji S, Melo JV. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 2005; 24(42): 6432-40.
25. Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006; 57: 145-64.
26. Deininger M. Resistance to imatinib: Mechanisms and management. J Natl Compr Canc Netw 2005; 3: 757-68.
27. Lionberger JM, Wilson MB, Smithgall TE. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 2000; 275: 18581-5.
28. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690-8.
29. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Ablindependent, Lyn dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004; 279: 34227-39.
30. Hu Y, Swerdlow S, Duffy TM, Dent P, Grant S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph +leukemia in mice. Proc Natl Acad Sci USA 2006; 103: 16870-5.
31. Meyn MA 3rd, Wilson MB, Abdi FA, et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem 2006; 281: 30907-16.
32. Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64: 672-7.
33. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brøndum-Nielsen K. Clonal Ph negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2002; 16: 1390-3.
34. Bumm T, Muller C, Al-Ali HK, et al. Emergence of clonal cytogenetic abnormalities in Ph cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941-9.
35. O'Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003; 17: 481-7.
36. Burchert A. Roots of imatinib resistance: A question of selfrenewal Drug Resist Updat 2007; 10: 152-61.
37. Baran Y, Salas A, Senkal CE, et al. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 2007; 282: 10922-34
38. Marfe G, Di Stefano C, Gambacurta A, et al. Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. Exp Hematol 2011; 39: 653-65.e6.
39. Yuan H, Wang Z, Li L, et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 2012; 119: 1904-14.
40. Li L, Wang L, Li L, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012; 21: 266-81.
41. Lee SM, Bae JH, Kim MJ, et al. Bcr-Abl-independent imatinib resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. J Pharmacol Exp Ther 2007; 322: 1084-92.
42. Wang Z, Yuan H, Roth M, Stark JM, Bhatia R, Chen WY. SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene 2013; 32: 589-98.
43. Kume S, Haneda M, Kanasaki K, et al. Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation. Free Radic Biol Med 2006; 40: 2175-82.
44. Chu F, Chou PM, Zheng X, Mirkin BL, Rebbaa A. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 2005; 65: 10183-7.
45. Hamad A, Sahli Z, El Sabban M, Mouteirik M, Nasr R. Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells. Stem Cells Int 2013; 2013: 724360.
46. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-70.
47. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-9.
48. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial. J Clin Oncol 2012; 28: 3486-92.
49. Müller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: Analysis of responses according to preexisting BCR-ABL mutations. Blood 2009; 24: 4944-53.
50. Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: What is the optimal strategy Mayo Clinic Proceedings 2009, 84: 161-9
51. Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood 2009; 114: 4933-8.
52. Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007; 109: 5011-5.
53. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinibresistant Bcr-Abl+ neoplastic cells. Cancer Res 2006; 66: 11314-22.
54. Keller-V Amsberg G, Brümmendorf TH. Novel aspects of therapy with the dual src and abl kinase inhibitor bosutinib in chronic myeloid leukemia. Expert Rev Anticancer Ther 2012; 12: 1121-7.
55. Deguchi Y, Kimura S, Ashihara E, et al. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 2008; 32: 980-3.
56. Kimura S, Naito H, Segawa H, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005; 106: 3948-54.
57. Kimura S, Ando T, Kojima K. Ever advancing chronic myeloid leukemia treatment. Int J Clin Oncol 2013 Nov 22. [Epub ahead of print].
58. Kantarjian H, le Coutre P, Cortes J, et al. Phase I study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosomepositive leukemias post-imatinib resistance or intolerance. Cancer 2010; 16: 2665-72.
59. Cortes J, Goldman JM, Hughes H. Current issues in chronic myeloid leukemia: Monitoring, resistance, and functional cure. J Natl Compr Canc Netw 2012; 10(suppl 3): S1-S13.
60. Ohanian M, Cortes J, Kantarjian H, Jabbour E. Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother 2012; 13: 927-38.
61. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a Pan-BCRABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance. Cancer Cell 2009; 16: 401-12.
62. Santos FPS, Kantarjian H, Quintás-Cardama A, Cortes J. Evolution of therapies for chronic myelogenous leukemia. Cancer J 2011; 17: 465-76.
63. O'Hare T, Zabriskie M, Eiring A, Deininger MW. Pushing the limits to targeted therapy in chronic myeloid leukemia. Nat Rev Cancer 2012; 12: 513-26.
64. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory philadelphia Chromosome-Positive leukemias. N Engl J Med 2012; 367: 2075-88.
65. Incerti M, Acquotti D, Sandor P, Vicini P. Synthesis and NMR spectral assignments of novel 1,4-benzothiazepine-5-one derivatives. Tetrahederon 2009; 65: 7487-90.
66. Rani P, Kishore D. An Overview of 1,5-Benzothiazepine. Int J Pharm Bio Sci 2013; 4: 779-88.
67. Bariwal JB, Upadhyay KD, Manvar AT, et al. 1, 5-Benzothiazepine, a versatile pharmacophore: A review. Eu J Med Chem 2008; 43: 2279-90.
68. Micheli F, Degiorgis F, Feriani A, et al. A combinational approach to 1, 5-benzothiazepine derivatives as potential antibacterial agents. J Comb Chem 2001; 3: 224-8.
69. Morton GC, Salvino JM, Labaudinière RF, Herpin TF. Novel solid phase synthesis of 1,5-benzothiazepine-4-one derivatives. Tetrahedron Lett 2000; 41: 3029-33.
70. Arya K, Dandia A. The expedient synthesis of 1,5-benzothiazepines as a family of cytotoxic drugs. Bioorganic and Medicinal Chem Letters 2008; 28: 114-9.
71. Sharma AK, Singh G, Yadav AK, Prakash L. Improved methods for the synthesis of 1, 5-benzothiazepine derivatives as analogues of anticancer drugs. Molecules 1997; 2: 129-34.
72. Silvestri R, Marfè G, Artico M, et al. Pyrrolo [1,2-b] [1,2,5]benzothiadiazepines (PBTDs): A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinibresistant. J Med Chem 2006; 49: 5840-4.
73. Marfe G, Di Stefano C, Silvestri R, et al. PYRROLO [1,2-b] [1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cells. BMC Cancer 2007; 7: 207.
74. Marfe G, Di Stefano C. In vitro anti-leukaemia activity of pyrrolo [ 1,2-b] [1,2,5]benzothiadiazepines (PBTDs). Recent Pat Anticancer Drug Discov 2010; 5: 58-68
75. Di Stefano C, Marfe G, Trawinska MM, et al. Pyrrolo [1,2-b] [1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patients. Cancer Sci 2010; 101: 991-1000.
76. Morotti A, Cilloni D, Messa F, et al. Valproate enhances imatinibinduced growth arrest and apoptosis in chronic myeloid leukemia cells. Cancer 2006; 106: 1188-1196.
77. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342-8
78. Kaulmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256: 42-9.
79. Reyes-Zurita FJ, Pachon-Pena G, Lizarraga D, Rufino-Palomares EE, Cascante M, Lupiáñez JA. The natural triterpene maslinic acid induces apoptosis in HT29 colon cancer cells by a JNK-p53-dependent mechanism. BMC Cancer 2011; 11: 154.
80. Kang MH, Reynolds CP. Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy. Clin Cancer Res 2009; 15: 1126-32.
81. McGowan AJ, Ruiz-Ruiz MC, Gorman AM, Lopez-Rivas A, Cotter TG. Reactive oxygen intermediate(s) (ROI): Common mediator( s) of poly(ADPribose) polymerase (PARP) cleavage and apoptosis. FEBS Lett 1996; 392: 299-303
82. Jaiswal S, Traver D, Miyamoto T, Akashi K, Lagasse E, Weissman IL. Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc Natl Acad Sci USA 2003; 100: 10002-7
83. Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, Scorilas A. The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias. Adv Hematol 2012; 2012: 52430
84. Zhuang J, Hawkins SF, Glenn MA, et al. Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: The therapeutic potential of Akt inhibition. Haematologica 2010; 95: 110-8.
85. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4EBP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003; 63: 5716-22
86. Dengler J, von Bubnoff N, Decker T, Peschel C, Duyster J. Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib. Leukemia 2005; 19: 1835-8.
87. Mayerhofer M, Aichberger KJ, Florian S, et al. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: Dissection of growth-inhibitory and VEGF suppressive effects of rapamycin in leukemic cells. FASEB J 2005; 19: 960-2.
88. Mohi MG, Boulton C, Gu TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004; 101: 3130-5.
89. Burchert A, Wang Y, Cai D, et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 2005; 19: 1774-82.
90. Melo JV, Chuah C. Novel agents in CML therapy: Tyrosine kinase inhibitors and beyond. Hematology Am Soc Hematol Educ Program 2008; 427-35